Navigation Links
Personalized Medicine in Oncology Partnering Terms and Agreements, a New Research Report at ReportsnReports.com
Date:1/12/2014

Dallas, Texas (PRWEB) January 12, 2014

The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the world’s leading healthcare companies.

The report “Personalized Medicine in Oncology Partnering Terms and Agreements - http://www.reportsnreports.com/reports/272325-personalized-medicine-in-oncology-partnering-terms-and-agreements.html” provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensor's personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of personalized medicine in oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine in oncology dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in personalized medicine in oncology partnering. The chapter also includes examples case studies of recent deals in personalized medicine in oncology partnering.

Chapter 3 provides a review of the leading personalized medicine in oncology deals since 2007. Deals are listed by headline value signed by all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of personalized medicine in oncology partnering deals signed and announced since January 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=272325.

The report also includes numerous tables and figures that illustrate the trends and activities in personalized medicine in oncology partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of personalized medicine in oncology technologies and products.

Report scope
Personalized Medicine in Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine in Oncology Partnering Terms and Agreements includes:

  •     Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2007
  •     Analysis of personalized medicine in oncology deal structure
  •     Case studies of real-life personalized medicine in oncology deals
  •     Access to over 600 personalized medicine in oncology deals
  •     The leading personalized medicine in oncology deals by value since 2007
  •     Most active personalized medicine in oncology dealmakers since 2007
  •     The leading personalized medicine in oncology partnering resources

In Personalized Medicine in Oncology Partnering Terms and Agreements , the available contracts are listed by:

  •     Headline value
  •     Stage of development at signing
  •     Deal component type
  •     Specific therapy target
  •     Specific technology target

Inquire for Discount on report @ http://www.reportsnreports.com/contacts/discount.aspx?name=272325.

Benefits
Personalized Medicine in Oncology Partnering Terms and Agreements provides the reader with the following key benefits:

  •     In-depth understanding of personalized medicine in oncology deal trends since 2007
  •     Analysis of the structure of personalized medicine in oncology agreements with numerous real life case studies
  •     Comprehensive access to over 600 personalized medicine in oncology deals entered into by the world’s biopharma companies
  •     Detailed access to actual personalized medicine in oncology contracts enter into by the leading fifty big pharma and big biotech companies
  •     Insight into the terms included in a personalized medicine in oncology agreement, together with real world clause examples
  •     Understand the key deal terms companies have agreed in previous deals
  •     Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Explore more reports by Current Partnering @ http://www.reportsnreports.com/publisher/current-partnering/ and Oncology Market.

About Us
ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth studies of 5000+ micro markets.

Read the full story at http://www.prweb.com/releases/personalized-medicine-in/oncology-partnering-terms/prweb11478529.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Personalized Blood Pressure Therapy May Help Diabetics
2. A new genre of diagnostic tests for the era of personalized medicine
3. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
4. New method may allow personalized clinical trial for cancer therapies
5. Personalized antiplatelet treatment improves outcome after PCI
6. Springer launches new book series on personalized medicine
7. The Olive Oil Source Introduces Valentine’s Day Labels for Personalized Olive Oil and Vinegar Gifts
8. Personalized plans to address barriers to HIV drug adherence boost chances of successful therapy
9. Custom Engraved Bamboo iPhone Case Sets New Benchmark in Personalized Protection
10. Rugged iPad Case with Personalized Barcode Tracking a Blessing for Schools
11. Personalized brain mapping technique preserves function following brain tumor surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 , ... ... decreases in medical payments per workers’ compensation claim in 2013 and 2014, according to ... Workers Compensation Research Institute (WCRI) . , According to the study, medical payments per ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael Insurance Agency, ... Hamilton County, is embarking on a charity drive with the aim of generating ... for orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally owned ... clients in the northern Alabama and Georgia regions, is embarking on a charity ... Works has built a network of support and education facilities to develop and ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
(Date:12/7/2016)... Atlanta, Georgia (PRWEB) , ... ... ... announced today it has acquired Presence Technology, S.L. (“Presence”) for a purchase ... certain price adjustments and other considerations. Presence’s annual revenue is approximately $13.2 ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch die CFDA sowie ... – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the Chinese Congress ... Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016  Boehringer Ingelheim announced today ... Equality Index (CEI). This is the ninth time that ... designated as a Best Place to Work for LGBT ... CEI is a national benchmarking report on corporate policies ... bisexual and transgender (LGBT) employees. "We ...
Breaking Medicine Technology: